Riskpilot← Back to searchSign inGet full accessInjectology AB
ABActiveOrg 5592383284Styrmansgatan 20Beauty care and other beauty treatment activities · NACE 9622Est. 20201-4 employees
Revenue 2025
SEK 1,8M
+4% vs 2024
EBITDA margin
-1.0%
-104% vs 2024
Equity ratio
91.7%
Financial strength
Net profit 2025
SEK 17K
-96% vs 2024
| Revenue | SEK 1,8M | +4% |
| EBITDA | SEK -18K | -104% |
| Net profit | SEK 17K | -96% |
| Total assets | SEK 1,9M | +1% |
| Equity | SEK 1,7M | +1% |
| Employees | — | — |
Legal name
Injectology AB
Org number
5592383284
Legal form
Aktiebolag
NACE code
9622 · Beauty care and other beauty treatment activities
Founded
23 januari 2020
Share capital
SEK 25 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Aktiebolaget ska bedriva en skönhetsklinik som genomför estetiska behandlingar samt injektionsbehandlingar i form av fillers och botox. Bolaget skall förvalta värdepapper samt förvalta fast och lösegendom.
Address
Styrmansgatan 20
Email
saliyounees@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 393 | 1 743 | 2 472 | 1 713 | 1 777 |
| Staff expenses | — | −423 | −765 | −720 | −1 003 |
| EBITDA | 274 | 561 | 759 | 460 | −18 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 274 | 561 | 759 | 460 | −18 |
| Net financials | — | 0 | 2 | 44 | 40 |
| Profit before tax | 273 | 561 | 761 | 505 | 22 |
| Tax | −56 | −116 | −157 | −104 | −5 |
| Net profit | 217 | 446 | 604 | 400 | 17 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 405 | 1 230 | 1 668 | 1 883 | 1 895 |
| Equity | 271 | 717 | 1 321 | 1 722 | 1 739 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 133 | 513 | 347 | 162 | 156 |
| Total debt | 133 | 513 | 347 | 162 | 156 |
EBITDA margin
-1.0%
This company
15.8%
Market median
-106% vs market
20212025
Equity ratio
91.7%
This company
38.2%
Market median
+140% vs market
20212025
Return on equity
1.0%
This company
18.4%
Market median
-95% vs market
20212025
Net profit margin
1.0%
This company
8.1%
Market median
-88% vs market
20212025
Asset turnover
0.94×
This company
1.12×
Market median
+16% vs market
20212025
Debt / equity
0.09×
This company
0.62×
Market median
+85% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
SY Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Injectology AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Sali Younes Bitar | Chief Executive Officer | 0 companies |
| Vian Faruk Hammo | Deputy Board Member | 0 companies |